ICPT
Income statement / Annual
Last year (2022), Intercept Pharmaceuticals, Inc.'s total revenue was $285.71 M,
a decrease of 21.39% from the previous year.
In 2022, Intercept Pharmaceuticals, Inc.'s net income was $115.17 M.
See Intercept Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$285.71 M
|
$363.47 M
|
$312.69 M
|
$252.00 M
|
$179.80 M
|
$130.96 M
|
$24.95 M
|
$2.78 M
|
$1.74 M
|
$1.62 M
|
| Cost of Revenue |
$984,000.00 |
$3.10 M |
$5.32 M |
$4.21 M |
$2.52 M |
$1.37 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$284.73 M |
$360.37 M |
$307.37 M |
$247.79 M |
$177.29 M |
$129.59 M |
$24.95 M |
$2.78 M |
$1.74 M |
$1.62 M |
| Gross Profit Ratio |
1 |
0.99 |
0.98 |
0.98 |
0.99 |
0.99 |
1 |
1 |
1 |
1 |
| Research and Development
Expenses |
$176.64 M
|
$185.27 M
|
$191.49 M
|
$242.80 M
|
$207.30 M
|
$191.50 M
|
$153.89 M
|
$128.19 M
|
$80.31 M
|
$27.94 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$255.47 M
|
$0.00
|
$0.00
|
$103.75 M
|
$34.60 M
|
$13.13 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$161.00
|
| Selling, General &
Administrative Expenses |
$176.30 M
|
$230.86 M
|
$332.49 M
|
$317.42 M
|
$255.47 M
|
$273.70 M
|
$273.60 M
|
$103.75 M
|
$34.60 M
|
$13.13 M
|
| Other Expenses |
$6.52 M |
$2.16 M |
$4.41 M |
$8.89 M |
$6.77 M |
$4.52 M |
$3.90 M |
$2.73 M |
$776,000.00 |
$100,375.00 |
| Operating Expenses |
$352.94 M |
$416.13 M |
$523.98 M |
$560.22 M |
$462.78 M |
$465.20 M |
$427.49 M |
$231.94 M |
$114.91 M |
$41.07 M |
| Cost And Expenses |
$353.93 M |
$419.23 M |
$529.30 M |
$564.43 M |
$465.29 M |
$466.57 M |
$427.49 M |
$231.94 M |
$114.91 M |
$41.07 M |
| Interest Income |
$15.51 M |
$47.77 M |
$39.80 M |
$33.35 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$21.39 M |
$54.42 M |
$48.05 M |
$41.14 M |
$30.52 M |
$29.27 M |
$14.20 M |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$6.52 M
|
$2.16 M
|
$4.41 M
|
$8.89 M
|
$4.58 M
|
$4.60 M
|
$3.83 M
|
$1.69 M
|
$442,797.00
|
$105,683.00
|
| EBITDA |
-$61.70 M
|
-$53.60 M
|
-$212.20 M
|
-$303.54 M
|
-$278.72 M
|
-$331.10 M
|
-$398.63 M
|
-$226.43 M
|
$57.66 M
|
-$10.90 M
|
| EBITDA Ratio |
-0.22 |
-0.15 |
-0.68 |
-1.2 |
-1.55 |
-2.53 |
-15.98 |
-81.39 |
33.1 |
-6.72 |
| Operating Income Ratio
|
-0.24
|
-0.15
|
-0.69
|
-1.24
|
-1.59
|
-2.56
|
-16.13
|
-82.37
|
-64.97
|
-24.33
|
| Total Other
Income/Expenses Net |
-$106.64 M
|
-$35.67 M
|
-$43.64 M
|
-$32.25 M
|
-$23.75 M
|
-$24.76 M
|
-$10.29 M
|
$2.73 M
|
-$170.06 M
|
-$28.34 M
|
| Income Before Tax |
-$174.86 M |
-$91.43 M |
-$274.88 M |
-$344.68 M |
-$309.24 M |
-$360.37 M |
-$412.83 M |
-$226.43 M |
-$283.23 M |
-$67.79 M |
| Income Before Tax Ratio
|
-0.61
|
-0.25
|
-0.88
|
-1.37
|
-1.72
|
-2.75
|
-16.55
|
-81.39
|
-162.59
|
-41.81
|
| Income Tax Expense |
-$290.03 M |
$53.60 M |
$49.35 M |
$46.37 M |
$6.77 M |
$29.19 M |
$14.27 M |
$1.04 M |
$170.39 M |
$28.44 M |
| Net Income |
$115.17 M |
-$145.02 M |
-$324.23 M |
-$391.05 M |
-$309.24 M |
-$360.37 M |
-$412.83 M |
-$226.43 M |
-$283.23 M |
-$67.79 M |
| Net Income Ratio |
0.4 |
-0.4 |
-1.04 |
-1.55 |
-1.72 |
-2.75 |
-16.55 |
-81.39 |
-162.59 |
-41.81 |
| EPS |
3.41 |
-4.55 |
-9.83 |
-12.35 |
-10.86 |
-14.38 |
-16.74 |
-9.56 |
-13.63 |
-3.76 |
| EPS Diluted |
3.4 |
-4.55 |
-9.83 |
-12.35 |
-10.86 |
-14.38 |
-16.74 |
-9.56 |
-13.63 |
-3.76 |
| Weighted Average Shares
Out |
$33.82 M
|
$31.86 M
|
$32.97 M
|
$31.65 M
|
$28.46 M
|
$25.05 M
|
$24.66 M
|
$23.69 M
|
$20.78 M
|
$18.03 M
|
| Weighted Average Shares
Out Diluted |
$33.84 M
|
$31.89 M
|
$32.97 M
|
$31.65 M
|
$28.46 M
|
$25.05 M
|
$24.66 M
|
$23.69 M
|
$20.78 M
|
$18.03 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
